Carnegie acted as adviser to Pharmacia and Biovitrum AB in the spin-off and equity financing of the biotechnology company Biovitrum AB from a division within Pharmacia to a consortium led by MPM Capital and Nordic Capital. Biovitrum AB is active in research into metabolic diseases and recombinant proteins. July, 2001.
Healthcare
Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion
July 2001